Recent Quotes (30 days)

You have no recent quotes
chg | %

Cardiome Pharma Corp.  

(Public, TSE:COM)   Watch this stock  
Find more results for COM
7.83
+0.33 (4.40%)
Apr 16 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 7.55 - 7.88
52 week 1.83 - 12.02
Open 7.59
Vol / Avg. 5,257.00/53,557.00
Mkt cap 128.87M
P/E 16.65
Div/yield     -
EPS 0.47
Shares 16.46M
Beta 1.17
Inst. own     -
May 12, 2014
Q1 2014 CARDIOME PHARMA CORP Earnings Release (Estimated) Add to calendar
Mar 27, 2014
Q4 2013 CARDIOME PHARMA CORP Earnings Release
Mar 27, 2014
Q4 2013 CARDIOME PHARMA CORP Earnings Conference Call
  

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -187.02% 105.81%
Operating margin -193.95% 91.71%
EBITD margin - -295.88%
Return on average assets -81.86% 10.36%
Return on average equity -135.44% 31.30%
Employees 75 -
CDP Score - -

Address

6TH FLOOR, 6190 AGRONOMY RD.
VANCOUVER, BC V6T 1Z3
Canada
+1-604-6776905 (Phone)
+1-604-6776915 (Fax)

Website links

Description

Cardiome Pharma Corp. (Cardiome) is a research-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of new therapies. It has one product, BRINAVESS, approved for marketing in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. The Company�s clinical programs are also focused on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. Cardiome also has several pre-clinical projects directed at various therapeutic indications. The Company operates primarily in one business segment with all of its assets located in Canada and operations located in Canada, the United States, Switzerland and the United Kingdom. In March 2012, the Company announced that Merck & Co., Inc. (Merck) discontinued further development of vernakalant (oral). In November 2013, Cardiome Pharma Corp. completed the acquisition of Correvio LLC.

Officers and directors

Robert W. Rieder Chairman of the Board
William L. Hunter M.D. President, Chief Executive Officer, Director
Age: 50
Jennifer Archibald Chief Financial Officer
Sheila M. Grant Chief Operating Officer
Karim Lalji Chief Commercial Officer
Richard M. Glickman Lead Independent Director
Peter W. Roberts CPA Independent Director
Harold H. Shlevin M.D., Ph.D., Independent Director
Age: 63